PARP inhibition: PARP1 and beyond

被引：1053

作者：

Rouleau, Michele ^{[1
]}

Patel, Anand ^{[2
]}

Hendzel, Michael J. ^{[4
]}

Kaufmann, Scott H. ^{[2
,3
]}

Poirier, Guy G. ^{[1
]}

机构：

[1] Univ Laval, Med Res Ctr, Quebec City, PQ, Canada

[2] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA

[3] Mayo Clin, Div Oncol Res, Rochester, MN USA

[4] Univ Alberta, Fac Med, Dept Oncol, Edmonton, AB T6G 2M7, Canada

来源：

NATURE REVIEWS CANCER | 2010年 / 10卷 / 04期

基金：

美国国家卫生研究院; 加拿大健康研究院;

关键词：

POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; ADENOSINE-DIPHOSPHATE-RIBOSE; DOUBLE-STRAND BREAKS; DNA-DAMAGING AGENTS; HUMAN GLIOMA-CELLS; HOMOLOGOUS RECOMBINATION; ADP-RIBOSYLATION; TELOMERE LENGTH; IN-VIVO; EMBRYONIC-DEVELOPMENT;

D O I：

10.1038/nrc2812

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets. To provide a framework for understanding these recent observations, we review what is known about the structures and functions of the family of PARP enzymes, and then outline a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.

引用

页码：293 / 301

页数：9

共 50 条

[1] PARP inhibition: PARP1 and beyond
Michèle Rouleau
Anand Patel
Michael J. Hendzel
Scott H. Kaufmann
Guy G. Poirier
Nature Reviews Cancer, 2010, 10 : 293 - 301
[2] Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
Shuai Wang
Lei Han
Jungsoo Han
Peng Li
Qing Ding
Qing-Jun Zhang
Zhi-Ping Liu
Chuo Chen
Yonghao Yu
Nature Chemical Biology, 2019, 15 : 1223 - 1231
[3] Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
Wang, Shuai
Han, Lei
Han, Jungsoo
Li, Peng
Ding, Qing
Zhang, Qing-Jun
Liu, Zhi-Ping
Chen, Chuo
Yu, Yonghao
NATURE CHEMICAL BIOLOGY, 2019, 15 (12) : 1223 - +
[4] PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
Wang, Luyao
Liang, Chao
Li, Fangfei
Guan, Daogang
Wu, Xiaoqiu
Fu, Xuekun
Lu, Aiping
Zhang, Ge
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
[5] PARP1 expression (PARP1expr) drives synergy between PARP1 inhibitors (PARP1-Is) and trabectedin (TR)
Pignochino, Ymera
Capozzi, Federica
D'ambrosio, Lorenzo
Dell'aglio, Carmine
Basirico, Marco
Boccone, Paola
Palesandro, Erica
Gammaitoni, Loretta
Sangiolo, Dario
Benassi, Maria Serena
Aglietta, Massimo
Grignani, Giovanni
CANCER RESEARCH, 2016, 76
[6] LiBERating PARP1
Beth Moorefield
Nature Structural & Molecular Biology, 2021, 28 : 535 - 535
[7] PARP1 and Atherosclerosis
Huo Qing-Wei
Li Dong-Feng
Long Cheng
PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2012, 39 (05) : 423 - 428
[8] PARP1 911
Florian J Bock
Paul Chang
Nature Chemical Biology, 2015, 11 (3) : 179 - 180
[9] Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, Junko
Huang, Shar-yin N.
Das, Benu Brata
Renaud, Amelie
Zhang, Yiping
Doroshow, James H.
Ji, Jiuping
Takeda, Shunichi
Pommier, Yves
CANCER RESEARCH, 2012, 72 (21) : 5588 - 5599
[10] LiBERating PARP1
Moorefield, Beth
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2021, 28 (07) : 535 - 535

← 1 2 3 4 5 →